ELIGIBILITY FOR AND USE OF HIV PRE-EXPOSURE PROPHYLAXIS AMONG AUSTRALIAN GAY AND BISEXUAL MEN OVER TIME

1Garrett Prestage, 1Mohamed Hammoud, 1Benjamin Bavinton*, 2Adam Bourne, 3Martin Holt, 4Stefanie Vaccher, 5Louisa Degenhardt, 1Lisa Maher, 1Phillip Keen, 1Bridge Haine, 6Andrew Grulich, 7Fengji Jin. 1UNSW Sydney, The Kirby Institute, Sydney, Australia; 2La Trobe University, Australian Research Centre in Sex Health and Society, Melbourne, Australia; 3UNSW Sydney, Centre for Social Research in Health, Sydney, Australia; 4The Kirby Institute, UNSW Sydney, Sydney, Australia; 5UNSW Sydney, National Drug and Alcohol Research Centre, Sydney, Australia; 7Kirby Institute, the University of New South Wales, Sydney, Australia

Background Gay and bisexual men (GBM) increasingly use HIV pre-exposure prophylaxis (PrEP) to prevent HIV infection. Eligibility for PrEP in Australia is based on behavioral criteria including methamphetamine use or condomless sex. It is unclear what proportions of GBM initiating PrEP meet these criteria over time.

Methods The Flux prospective cohort study enrolled Australian GBM between 2014 and 2018, following them every six months. We report PrEP use and behavioral eligibility for PrEP over time. Sexually transmissible infections data were not collected.

Results Among 1518 non-HIV-positive men who were not using PrEP at baseline, mean age was 37.2 years (SD 13.13). Incident PrEP use increased from 2.8% at visit 2 to 11.9% at visit 6 (p-trend<0.001); eligibility for PrEP increased from 24.5% at baseline to 34.1% at visit 5 but fell to 20.4% at visit 6. Among all PrEP non-users, over one third were eligible for PrEP at some time during follow-up: 22.9% were eligible at visit 2; this proportion remained stable over subsequent visits (21.5% at visit 5) but fell to 9.6% at visit 6. Less than 1% of PrEP users subsequently ceased use. Among continuing PrEP users, the proportion of non-eligible men remained steady at about 25% over time. Similar proportions (about 10%) became eligible as ceased being eligible between visits.

Conclusion Although PrEP use or non-use was largely consistent with behavioral criteria for eligibility for its use, a substantial minority of GBM did not appear to use PrEP according to eligibility guidelines. About one-quarter of men who used PrEP were not eligible at the time while a similar proportion of PrEP non-users were eligible for its use, suggesting some underestimation of HIV risk. Greater efforts are needed to address these discrepancies between PrEP eligibility and its use, as engagement in risk behaviors changes over time.

Disclosure No significant relationships.

ANXIETY ABOUT HIV AND USE OF HIV PRE-EXPOSURE PROPHYLAXIS AMONG GAY AND BISEXUAL MEN

1Garrett Prestage, 1Phillip Keen, 1Mohamed Hammoud, 2Adam Bourne, 1Benjamin Bavinton, 2Martin Holt, 3Stefanie Vaccher, 3Peter Sexton, 1Lisa Maher, 1Bridge Haine, 7Fengji Jin. 1UNSW Sydney, The Kirby Institute, Sydney, Australia; 2La Trobe University, Australian Research Centre in Sex Health and Society, Melbourne, Australia; 3UNSW Sydney, Centre for Social Research in Health, Sydney, Australia; 4The Kirby Institute, UNSW Sydney, Sydney, Australia; 5University of Auckland, School of Population Health, Auckland, New Zealand

Background Many gay and bisexual men (GBM) experience anxiety about HIV, particularly in relation to sex. Use of HIV pre-exposure prophylaxis (PrEP) as an HIV prevention strategy may affect levels of HIV-related anxiety among GBM.

Methods Flux is an Australian online prospective study of GBM enrolled between 2014 and 2018. We measured anxiety using the generalized anxiety disorder assessment (GAD7) scale and a newly developed HIV anxiety scale developed using Principal Components Analysis. We assessed behavioral eligibility for PrEP based on Australian PrEP clinical prescribing guidelines. We used multivariate logistic regression to assess associations between use of PrEP and both GAD7 and HIV-specific anxiety.

Results Among 1574 men who completed the HIV anxiety scale, mean age was 37.2 years (SD 13.13). Men aged 25 years or younger had higher HIV anxiety scores than their older counterparts (p<0.001). Men who reported condomless anal intercourse with casual partners (CLAIC) scored higher on HIV anxiety than men who reported no CLAIC (p=0.033). Among 1168 men who were not eligible for PrEP in the UK is either through a clinical study with limited capacity or by purchasing online. Dosing schedules are usually self-selected, often without access to professional advice or evidenced-based information. Non-daily dosing is popular as it is believed to be less toxic and more affordable than daily dosing.

Methods We describe three cases of HIV acquisition despite use of PrEP

Results All were MSM and had a negative antigen/antibody HIV tests at 3 months of use. Case 1 switched to EBD after one month of daily PrEP. After several months he switched back to daily PrEP and had a positive HIV-1 antibody test six weeks later. Case 2 switched to EBD after 5 months of daily PrEP due to lower frequency of sex. He reported excellent adherence. He had a positive HIV-1 antibody test 4 months later. Case 3 was taking EBD PrEP for a total of 9 months. He had a positive HIV-1 antibody 5 months after his last negative HIV test. This was two months after his last episode of condomless sex. He reported occasional late dosing and some use of recreational drugs.

Conclusion It is likely that all three cases became infected while taking event-based PrEP. Two cases switched between daily and EBD due to lower self-perceived risk of HIV or frequency of sex. It is not clear if this may have affected PrEP efficacy. Evidence for effective EBD is strongly dependent on adherence and timing of doses. It is therefore vital that PrEP provision includes objective HIV risk assessment, adherence support and evidence-based dosing information to optimise efficacy.

Disclosure No significant relationships.

A CASE SERIES OF PRE-EXPOSURE PROPHYLAXIS FAILURES IN MEN USING EVENT-BASED-DOSING IN LONDON, UK

1Naomi Fitzgerald*, 1Achyuta Nori. 1Guy’s and St Thomas’ NHS Trust, Burrell Street Sexual Health Clinic, London, UK; 2Guys and St Thomas’s NHS Foundation Trust, London, UK

Background British guidelines recommend both event-based dosing (EBD) and daily dosing of combined tenofovir/emtricitabine (TDF/FTC) for HIV pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM). Access to PrEP in London, UK is either through a clinical study with limited capacity or by purchasing online. Dosing schedules are usually self-selected, often without access to professional advice or evidenced-based information. Non-daily dosing is popular as it is believed to be less toxic and more affordable than daily dosing.

Methods We describe three cases of HIV acquisition despite use of PrEP

Results All were MSM and had a negative antigen/antibody HIV tests at 3 months of use. Case 1 switched to EBD after one month of daily PrEP. After several months he switched back to daily PrEP and had a positive HIV-1 antibody test six weeks later. Case 2 switched to EBD after 5 months of daily PrEP due to lower frequency of sex. He reported excellent adherence. He had a positive HIV-1 antibody test 4 months later. Case 3 was taking EBD PrEP for a total of 9 months. He had a positive HIV-1 antibody 5 months after his last negative HIV test. This was two months after his last episode of condomless sex. He reported occasional late dosing and some use of recreational drugs.

Conclusion It is likely that all three cases became infected while taking event-based PrEP. Two cases switched between daily and EBD due to lower self-perceived risk of HIV or frequency of sex. It is not clear if this may have affected PrEP efficacy. Evidence for effective EBD is strongly dependent on adherence and timing of doses. It is therefore vital that PrEP provision includes objective HIV risk assessment, adherence support and evidence-based dosing information to optimise efficacy.

Disclosure No significant relationships.